5242802026-01-012026-03-315242802026-03-315242802025-03-315242802025-04-012026-03-315242802026-01-012026-03-31in-capmkt:OtherExpenses1Member5242802026-01-012026-03-31in-capmkt:OtherExpenses2Member5242802025-04-012026-03-31in-capmkt:OtherExpenses1Member5242802025-04-012026-03-31in-capmkt:OtherExpenses2Member5242802026-03-31OtherNoncurrentFinancialAssetsDomain15242802026-03-31OtherNoncurrentFinancialAssetsDomain25242802026-03-31OtherCurrentFinancialAssetsDomain15242802026-03-31OtherCurrentAssetsDomain15242802026-03-31OtherCurrentFinancialLiabilitiesDomain15242802026-03-31OtherCurrentLiabilitiesDomain15242802026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15242802025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15242802026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15242802025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15242802026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524280KOPRANNOTLISTEDINE082A01010KOPRAN LIMITEDMain BoardEquity2025-04-012026-03-312026-05-192026-05-06INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2026-05-1911:30:002026-05-1914:30:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated23401830009040002341087000139929400018395000477580001645570003170800045158000380728000208759800025348900002534890005783300070010006483400001886550000000188655000104720001991270000000482856000103.913.91003.913.911) The above Statement of consolidated and standalone audited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with Companies (lndian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in lndia. There is no minority interest. <BR> 2) The above Statement of consolidated and standalone audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 19, 2026. The Statutory Auditors do not have any modification/qualification. <BR> 3) The Company and the subsidiaries together referred to as "Group" are engaged primarily in the Pharmaceuticals business and there are no separate reportable segments as per Ind AS 108 on " Operating Segment Reporting". <BR> 4) The Government of India, vide notification dated November 21, 2025, has notified the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the “New Labour Codes”), which consolidate and replace twenty-nine existing central labour laws into unified framework governing employee benefits during employment and post-employment. The New Labour codes, amongst other things introduced changes, including a uniform definition of wages for statutory purposes. Once Central / State Rules are notified by the Government on all aspects of the Codes, the management of the company will evaluate its impact, on the employee benefits and provide for the same in the books of accounts, if necessary. <BR> <BR> 5) The Board of Directors of Kopran Limited and Kopran Laboratories Limited in their Board Meetings held on 20th March, 2025 and subsequently on 8th August, 2025 have subject to the approval of Stock Exchanges, shareholders, National Company Law Tribunal (NCLT) and other relevant Authorities, proposed and approved a Scheme of Amalgamation ( Merger by absorption) between Kopran Laboratories Limited the Transferor Company and Kopran Limited the Transferee Company and their respective shareholders. The Appointed Date is 1st January, 2025. The Company has received “NO Adverse Observation /observation letter ” for the proposed Scheme of amalgamation from BSE Limited and National Stock Exchange of India Limited (NSE) where the shares of the Company are listed. The Hon’ble National Company Law Tribunal (NCLT) Mumbai Bench, Mumbai vide its Order 9th April, 2026 have admitted the Application and issued various directions including convening the meetings of Equity Shareholders and Creditors. Said meeting as per the NCLT directions will be held on Wednesday the 3rd June, 2026. The effect of the Scheme will be given in the books of accounts only after the Hon’ble NCLT Mumbai Bench sanctions the Scheme of Amalgamation. <BR> <BR> 6) Figures for the previous period have been regrouped or reclassified, wherever necessary to make them comparable with the figures of the current period.2025-04-012026-03-31AuditedConsolidated6814236000345700068176930004311817000373820004095600065213100010471500017472700011524030006474131000343562000034356200090361000-41110008625000002573120000000257312000518500026249700000004828560001048199490005.335.33005.335.33Other exepense304453000Foreign Exchange Loss76275000Other exepense992946000Foreign Exchange Loss159457000337047000023266000058000939540002246190000056600000138924000139490000038518570001642078000026265710006820000654020008145100093300027811770001512100079339100052317670000090836240004828560004819949000530280500005302805000139481000000139481000894020009013500003190180001387444000959040001482265000157816900039675300033623660005471500015180000295400000346180100037808190009083624000Others58191000Other non-current financial assets80733000Others933000Other current assets793391000Other current financial liabilities396753000Other current liabilities5471500010471500052154000-45117100000865260000-1123200003869780000-6036400001747270007058000001183760000-27225000029880000000203100018380000381423000724985000000574780000667507000000000002500005847730000008647800000000000-3032000-189960000000298800000-645985000000000006643000026298000014485700010470500000-209430000-1879080000-1879080001947280006820000Remeasurement of defined benefit plans1286600012866000Remeasurement of defined benefit plans4156000415600032380001047000Exchange difference in translating the financial statement of foreign operation844000844000Exchange difference in translating the financial statement of foreign operation2076000207600000104720005185000AuditedtrueKhandelwal Jain & Cotrue2028-08-31